It is a hopeful time of year for the European Alliance for Personalised Medicine (EAPM) as spring finally unveils itself across the EU and coronavirus vaccinations proceed apace, writes EAPM Executive Director Dr. Denis Horgan. New newsletter, 9th EU Presidency Conference The latest EAPM newsletter is now available for your attention, and it has much in there to […]
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma. Shares of the combined company, which is operating under the name Viracta Therapeutics, Inc., will commence trading on the Nasdaq Global Select Market under the ticker symbol "VIRX" on February 25, 2021.
Converge Biotech, OncoDNA offer personalised cancer care
Converge Biotech, OncoDNA offer personalised cancer care
09 February 2021 | News OncoDNA’s solutions are designed to guide oncologists in the selection of the most appropriate treatments based on the specific tumour profile of a patient
Source credit: Shutterstock
Converge Biotech, a leading healthcare organisation based in Hyderabad has announced that it has entered into a long-term strategic alliance with OncoDNA, a Belgium-based theranostic and genomic company specialising in precision oncology, to personalise care for late-stage cancer patients across India. OncoDNA’s solutions are designed to guide oncologists in the selection of the most appropriate treatments based on the specific tumour profile of a patient.